Literature DB >> 16304194

Assessing the in vitro effectiveness of antimicrobials against Mycoplasma mycoides subsp. mycoides small-colony type to reduce contagious bovine pleuropneumonia infection.

R D Ayling1, S Bisgaard-Frantzen, J B March, K Godinho, R A J Nicholas.   

Abstract

In vitro minimum inhibitory concentrations were determined for 21 antimicrobials against 41 isolates of Mycoplasma mycoides subsp. mycoides small-colony type, the cause of contagious bovine pleuropneumonia. Of the antimicrobials used most widely in Africa, oxytetracycline and tilmicosin were effective, while the isolates were resistant to tylosin. These results provide a baseline for monitoring antimicrobial resistance.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16304194      PMCID： PMC1315977          DOI： 10.1128/AAC.49.12.5162-5165.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  6 in total

1.  Comparison of in vitro activity of danofloxacin, florfenicol, oxytetracycline, spectinomycin and tilmicosin against Mycoplasma mycoides subspecies mycoides small colony type.

Authors:  R D Ayling; S E Baker; R A Nicholas; M L Peek; A J Simon
Journal:  Vet Rec       Date:  2000-02-26       Impact factor: 2.695

2.  Danofloxacin treatment of cattle affected by CBPP.

Authors:  Otto Hübschle; Kevin Godinho; Tim Rowan; Robin Nicholas
Journal:  Vet Rec       Date:  2004-09-25       Impact factor: 2.695

Review 3.  Recovery of mycoplasmas from animals.

Authors:  R Nicholas; S Baker
Journal:  Methods Mol Biol       Date:  1998

4.  A comparison of serological tests and gross lung pathology for detecting contagious bovine pleuropneumonia in two groups of Italian cattle.

Authors:  R A Nicholas; F G Santini; K M Clark; N M Palmer; P De Santis; J B Bashiruddin
Journal:  Vet Rec       Date:  1996-07-27       Impact factor: 2.695

5.  A PCR-based test for the specific identification of Mycoplasma mycoides subspecies mycoides SC.

Authors:  J B Bashiruddin; T K Taylor; A R Gould
Journal:  J Vet Diagn Invest       Date:  1994-10       Impact factor: 1.279

6.  Contagious bovine pleuropneumonia (CBPP) caused by vaccine strain T1/44 of Mycoplasma mycoides subsp. mycoides SC.

Authors:  Rosa-Stella Mbulu; Georgina Tjipura-Zaire; Rosella Lelli; Joachim Frey; Paola Pilo; Edy M Vilei; Felix Mettler; Robin A J Nicholas; Otto J B Huebschle
Journal:  Vet Microbiol       Date:  2004-03-05       Impact factor: 3.293
  6 in total
  6 in total

1.  Antimicrobial susceptibility and multilocus sequence typing of Mycoplasma capricolum subsp. capricolum.

Authors:  Juan Tatay-Dualde; Miranda Prats-van der Ham; Christian de la Fe; Ana Paterna; Antonio Sánchez; Juan Carlos Corrales; Antonio Contreras; Sebastiana Tola; Ángel Gómez-Martin
Journal:  PLoS One       Date:  2017-03-27       Impact factor: 3.240

Review 2.  Contagious Agalactia In Sheep And Goats: Current Perspectives.

Authors:  Maryne Jaÿ; Florence Tardy
Journal:  Vet Med (Auckl)       Date:  2019-12-27

3.  [Present Situation of Contagious Bovine Pleuropneumonia in Central African Republic].

Authors:  P Ngounda; L Manso-Silván; F Thiaucourt
Journal:  Med Trop Sante Int       Date:  2021-05-17

4.  Pharmacodynamics of antimicrobials against Mycoplasma mycoides mycoides small colony, the causative agent of contagious bovine pleuropneumonia.

Authors:  John D Mitchell; Quintin A McKellar; Declan J McKeever
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

5.  Mycoplasmas are no exception to extracellular vesicles release: Revisiting old concepts.

Authors:  Patrice Gaurivaud; Sarah Ganter; Alexandre Villard; Lucia Manso-Silvan; Didier Chevret; Christelle Boulé; Véronique Monnet; Florence Tardy
Journal:  PLoS One       Date:  2018-11-28       Impact factor: 3.240

Review 6.  Transboundary Animal Diseases, an Overview of 17 Diseases with Potential for Global Spread and Serious Consequences.

Authors:  Elizabeth A Clemmons; Kendra J Alfson; John W Dutton
Journal:  Animals (Basel)       Date:  2021-07-08       Impact factor: 2.752
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.